{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:53:34Z","timestamp":1759366414393,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.revmed.2007.01.022","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T17:21:25Z","timestamp":1173374485000},"page":"537-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avanc\u00e9es r\u00e9centes et\u00a0perspectives dans\u00a0le\u00a0traitement des\u00a0dyslipid\u00e9mies ath\u00e9rog\u00e8nes"],"prefix":"10.1016","volume":"28","author":[{"given":"F.","family":"Cohen Aubart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-S.","family":"Hulot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lechat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2007.01.022_bib1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0735-1097(02)02609-8","article-title":"Low-density lipoprotein lowering therapy: an analysis of the options","volume":"40","author":"Sacks","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2007.01.022_bib4","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2007.01.022_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2007.01.022_bib7","first-page":"1788","volume":"55","year":"2005","journal-title":"Rev. Prat."},{"key":"10.1016\/j.revmed.2007.01.022_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.pharmthera.2006.02.003","article-title":"Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease","volume":"111","author":"Chapman","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.01.022_bib9","doi-asserted-by":"crossref","first-page":"60E","DOI":"10.1016\/j.amjcard.2005.06.007","article-title":"Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks","volume":"96","author":"McKenney","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.clinthera.2004.09.005","article-title":"Rosuvastatin in the management of hyperlipidemia","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.revmed.2007.01.022_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ajhp\/62.10.1033","article-title":"Efficacy and safety of rosuvastatin in treatment of dyslipidemia","volume":"62","author":"McKenney","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.revmed.2007.01.022_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1185\/030079903125002405","article-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial","volume":"19","author":"McKenney","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.revmed.2007.01.022_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0735-1097(98)00300-3","article-title":"Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin","volume":"32","author":"Brown","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib19","doi-asserted-by":"crossref","first-page":"50K","DOI":"10.1016\/S0002-9149(02)02970-3","article-title":"Combination therapy for dyslipidemia: safety and regulatory considerations","volume":"90","author":"Davidson","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib20","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1067\/mhj.2002.128049","article-title":"Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia","volume":"144","author":"Olsson","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.revmed.2007.01.022_bib21","first-page":"73","article-title":"Rosuvastatin: an independent analysis of risks and benefits","volume":"8","author":"Zipes","year":"2006","journal-title":"MedGenMed"},{"key":"10.1016\/j.revmed.2007.01.022_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0091270005278224","article-title":"Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics","volume":"45","author":"Simonson","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.revmed.2007.01.022_bib23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2007.01.022_bib24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(06)68728-X","article-title":"Spinning stars: ASTEROID's impact on atherosclerosis","volume":"367","author":"Schachter","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib25","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.revmed.2007.01.022_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11886-004-0052-5","article-title":"Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways","volume":"6","author":"Patel","year":"2004","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.revmed.2007.01.022_bib29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.revmed.2007.01.022_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.32.3.314","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.revmed.2007.01.022_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.revmed.2007.01.022_bib32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.revmed.2007.01.022_bib33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0022-2275(20)39690-5","article-title":"Assessment of percent cholesterol absorption in humans with stable isotopes","volume":"34","author":"Bosner","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.revmed.2007.01.022_bib34","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib35","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2007.01.022_bib36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.revmed.2007.01.022_bib39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000116766.31036.03","article-title":"Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia","volume":"109","author":"Salen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2007.01.022_bib40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2007.01.022_bib43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/01.ATV.0000142804.27420.5b","article-title":"Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease","volume":"24","author":"Brewer","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.revmed.2007.01.022_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00041433-199908000-00007","article-title":"Scavenger receptor BI and cholesterol trafficking","volume":"10","author":"Williams","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.revmed.2007.01.022_bib45","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1194\/jlr.M300511-JLR200","article-title":"Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans","volume":"45","author":"Schwartz","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.revmed.2007.01.022_bib46","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMcp044370","article-title":"Clinical practice. Low HDL cholesterol levels","volume":"353","author":"Ashen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib47","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib49","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0140-6736(04)16359-9","article-title":"The nicotinic acid receptor--a new mechanism for an old drug","volume":"363","author":"Karpe","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bcp.2003.09.014","article-title":"Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin","volume":"67","author":"Rubic","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.revmed.2007.01.022_bib51","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI109385","article-title":"Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism","volume":"63","author":"Shepherd","year":"1979","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.revmed.2007.01.022_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","author":"Brown","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9149(00)01410-7","article-title":"Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia","volume":"87","author":"Wolfe","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.revmed.2007.01.022_bib54","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","article-title":"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C","volume":"20","author":"Chapman","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.revmed.2007.01.022_bib55","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.revmed.2007.01.022_bib56","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2007.01.022_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.revmed.2007.01.022_bib58","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.01.022_bib59","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.ATV.19.5.1257","article-title":"Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice","volume":"19","author":"Franceschini","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.revmed.2007.01.022_bib60","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2007.01.022_bib61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.revmed.2007.01.022_bib62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1194\/jlr.M500349-JLR200","article-title":"Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action","volume":"47","author":"Clark","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.revmed.2007.01.022_bib63","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.revmed.2007.01.022_bib64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2007.01.022_bib65","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866307000616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866307000616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:20:54Z","timestamp":1759335654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866307000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0248866307000616"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2007.01.022","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avanc\u00e9es r\u00e9centes et\u00a0perspectives dans\u00a0le\u00a0traitement des\u00a0dyslipid\u00e9mies ath\u00e9rog\u00e8nes","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2007.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}